# Olanzapine for the Prevention of Postoperative Nausea and Vomiting

> **NCT04718727** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amani Hassan Abdel-Wahab** · enrollment: 132 (actual)

## Conditions studied

- Postoperative Nausea

## Interventions

- **DRUG:** Placebo
- **DRUG:** 5 mg Olanzapine Tablets
- **DRUG:** 10 mg Olanzapine Tablets

## Key facts

- **NCT ID:** NCT04718727
- **Lead sponsor:** Amani Hassan Abdel-Wahab
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718727, "Olanzapine for the Prevention of Postoperative Nausea and Vomiting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04718727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*